# Medicare Covers GLP-1 Drugs for Weight Loss Starting July 1
Medicare launches a new pilot program on July 1 that covers GLP-1 receptor agonist drugs for weight loss alone, marking the first time the federal health program pays for these medications when used solely for weight management rather than diabetes treatment.
The pilot covers semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) for beneficiaries with a body mass index of 30 or higher, or 27 or higher with weight-related conditions like hypertension or sleep apnea. Participants must also complete behavioral counseling focused on nutrition and physical activity.
This decision reflects shifting federal priorities around obesity treatment. GLP-1 drugs work by mimicking hormones that regulate appetite and blood sugar, leading to weight loss of 15 to 22 percent in clinical trials. The Centers for Medicare and Medicaid Services (CMS) chose a pilot approach to gather real-world effectiveness and safety data before potentially expanding coverage.
The program includes important requirements. Beneficiaries must obtain prior authorization before starting treatment. Coverage continues only if patients lose at least 5 percent of their baseline weight within 6 months and maintain this loss. The pilot runs through December 2025, affecting roughly 3,200 Medicare beneficiaries initially.
Cost represents a major consideration. These drugs retail for roughly $900 to $1,350 per month without insurance. Medicare's coverage removes this barrier for eligible seniors, though out-of-pocket costs vary based on plan type.
Specialists including endocrinologists and primary care physicians can prescribe these medications under the pilot. However, access remains limited. Many Medicare beneficiaries in rural areas face shortages of prescribers trained in GLP-1